Imusat film-coated tablets 100 mg blister 10 pcs

Active ingredient: umifenovir;

1 tablet contains umifenovir 50 mg or 100 mg;

potato starch, methylcellulose, colloidal anhydrous silicon dioxide, calcium stearate, Opadry II 85F white.

Antivirals for systemic use. Other antiviral drugs. ATX code J05A X13.

The pills are coated.

Main physicochemical properties: film-coated tablets, white or white with a creamy tint, biconvex shape.

Pharmacodynamics. Antiviral agent, specifically inhibits influenza A and B viruses, including highly pathogenic subtypes A (H1N1) pdm09 and A (H5N1). According to the mechanism of antiviral action, it belongs to fusion inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid envelope of the virus and cell membranes.

Therapeutic efficacy in influenza is manifested in reducing the duration and severity of the disease and its main symptoms, as well as in reducing the frequency of complications associated with influenza.

The drug belongs to low-toxic drugs and does not have a negative effect on the human body when used in recommended doses.

Pharmacokinetics. The drug is rapidly absorbed in the digestive tract. C _max in blood plasma is reached when taken at a dose of 50 mg after 1.2 hours, at a dose of 100 mg – after 1.5 hours after administration. T _½ is 17-21 hours. About 40% of the drug is excreted unchanged: with feces (38.9%) and urine (0.12%). During the first day, 90% of the dose taken is excreted.

Prevention and treatment of influenza a and c.

For adults. Take orally before meals. Single dose is 200 mg.

For prevention:

in direct contact with flu patients: 200 mg once a day for 10-14 days;

during the flu epidemic: 200 mg 2 times a week for 3 weeks.

For the treatment of influenza: 200 mg 4 times a day (every 6 hours) for 5 days.

The maximum daily dose is 800 mg.

Hypersensitivity to the active substance or other components of the drug.

Immune system disorders: hypersensitivity reactions, including skin redness, itching, rash, urticaria, angioedema.

Gastrointestinal changes, including heartburn, epigastric heaviness, vomiting.

Use with caution:

Elderly patients (since safety and efficacy in elderly patients have not been sufficiently studied);
patients with impaired liver and kidney function (since pharmacokinetics and safety in such patients have not been studied).
There are no data on the use of the drug for a long time.

Use during pregnancy and breastfeeding. The safety of use during pregnancy and breastfeeding has not been sufficiently studied.

Children: Do not use in children.

Ability to influence the reaction rate when driving vehicles or working with other mechanisms. In recommended doses, it does not affect the reaction rate when driving vehicles or working with other mechanisms.

No negative effects were detected when the drug interacted with other medications.

Not marked.

50 mg pills – 2 years.

100 mg pills – 3 years.

10 tablets in a contour cell packaging; 1 contour cell packaging in a pack.

In the original packaging at a temperature not exceeding 25 °C.